Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
MedicalDaily Evidence Check The evidence base for BPC-157, TB-500, and MOTS-C consists of animal studies, small pilot human trials, and anecdotal clinical reports, none of which meet the standard of a Phase 3 randomized controlled trial required for FDA drug approval
The two principal combinations are BPC-157 plus TB-500 (mechanistically distinct, pentadecapeptide signalling plus actin sequestration), and BPC-157 plus TB-500 plus GHK-CU (three-compound research design covering pentadecapeptide, thymosin family, and copper tripeptide pathways)
Verification also involves confirming proper storage conditions
It was first studied in the 1990s for its tissue healing and repair properties
Do you need something else
At Evexia Medspa, serving the DMV areas, we are committed to supporting your well-being and helping you thrive in all aspects of life
US$ 23.82
US$ 21.68
US$ 25.94
US$ 22.37
US$ 27.20
